SCHEMBL2884183

SCHEMBL2884183

OC1CCCCCC([N+]2(Cc3ccccc3)CCCCCC(O)C2)C1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.35
SLC18A3 Q16572 3/20 0.33
EPHX2 P34913 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNA4 P43681 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
EPHX1 P07099 1/20 0.31
HPGD P15428 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SIGMAR1 Q99720 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7192200 0.79 MEN1 (0.41) MEN1KMT2AALDH1A1EPHX2CHRNB2
SCHEMBL8965756 0.79 MEN1 (0.41) MEN1KMT2AALDH1A1EPHX2CHRNB2
SCHEMBL10256701 0.68 ACHE (0.43) MEN1KMT2AALDH1A1CHRNB2CHRNA4
SCHEMBL4282417 0.68 EED (0.37) MEN1KMT2ACHRNB2CHRNA4
SCHEMBL253686 0.66 POLB (0.44) MEN1KMT2ATAAR1
SCHEMBL14986054 0.65 MEN1 (0.49) MEN1KMT2ACHRNB2CHRNA4CHRNB4
SCHEMBL8056836 0.65 HTT (0.42) ALDH1A1CHRNB2CHRNA4HTTL3MBTL1
SCHEMBL8965651 0.65 HTT (0.42) ALDH1A1CHRNB2CHRNA4HTTL3MBTL1
SCHEMBL3974938 0.64 MEN1 (0.49) MEN1KMT2AALDH1A1CHRNB2CHRNA4
SCHEMBL10265766 0.64 CHRM3 (0.49) MEN1KMT2ASLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 MEN1 2995/4885KMT2A 2466/4885ALDH1A1 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.